Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 268

1.

Low-dose agalsidase beta treatment in male pediatric patients with Fabry disease: A 5-year randomized controlled trial.

Ramaswami U, Bichet DG, Clarke LA, Dostalova G, Fainboim A, Fellgiebel A, Forcelini CM, An Haack K, Hopkin RJ, Mauer M, Najafian B, Scott CR, Shankar SP, Thurberg BL, Tøndel C, Tylki-Szymanska A, Bénichou B, Wijburg FA.

Mol Genet Metab. 2019 Apr 3. pii: S1096-7192(18)30766-2. doi: 10.1016/j.ymgme.2019.03.010. [Epub ahead of print]

2.

Cancer events in Belgian nursing home residents: An EORTC prospective cohort study.

Wildiers H, Mauer M, Elseviers M, De Wolf J, Hatse S, Hamaker M, Buntinx F, De Lepeleire J, Uytterschaut G, Falandry C, Tryfonidis K, Janssen-Heijnen M.

J Geriatr Oncol. 2019 Mar 18. pii: S1879-4068(19)30001-3. doi: 10.1016/j.jgo.2019.03.005. [Epub ahead of print]

3.

Genetic Determinants of Glycated Hemoglobin in Type 1 Diabetes.

Syreeni A, Sandholm N, Cao J, Toppila I, Maahs DM, Rewers MJ, Snell-Bergeon JK, Costacou T, Orchard TJ, Caramori ML, Mauer M, Klein BEK, Klein R, Valo E, Parkkonen M, Forsblom C, Harjutsalo V, Paterson AD; DCCT/EDIC Research Group, Groop PH; FinnDiane Study Group.

Diabetes. 2019 Apr;68(4):858-867. doi: 10.2337/db18-0573. Epub 2019 Jan 23.

PMID:
30674623
4.

Inappropriate Grading of Adverse Events in Cancer Clinical Trials-Reply.

Cristina V, Mauer M, Wagner AD.

JAMA Oncol. 2018 Dec 13. doi: 10.1001/jamaoncol.2018.5871. [Epub ahead of print] No abstract available.

PMID:
30543369
5.

Urine inositol pentakisphosphate 2-kinase and changes in kidney structure in early diabetic kidney disease in type 1 diabetes.

Looker HC, Merchant ML, Rane MJ, Nelson RG, Kimmel PL, Rovin BH, Klein JB, Mauer M; CKD Biomarkers Consortium.

Am J Physiol Renal Physiol. 2018 Nov 1;315(5):F1484-F1492. doi: 10.1152/ajprenal.00183.2018. Epub 2018 Aug 22.

PMID:
30132343
6.

Lapatinib with ECF/X in the first-line treatment of metastatic gastric cancer according to HER2neu and EGFR status: a randomized placebo-controlled phase II study (EORTC 40071).

Moehler M, Schad A, Maderer A, Atasoy A, Mauer ME, Caballero C, Thomaidis T, John JMM, Lang I, Van Cutsem E, Freire J, Lutz MP, Roth A; EORTC Gastrointestinal Tract Cancer Group.

Cancer Chemother Pharmacol. 2018 Oct;82(4):733-739. doi: 10.1007/s00280-018-3667-8. Epub 2018 Aug 13.

PMID:
30105460
7.

Biological Variability of Estimated GFR and Albuminuria in CKD.

Waikar SS, Rebholz CM, Zheng Z, Hurwitz S, Hsu CY, Feldman HI, Xie D, Liu KD, Mifflin TE, Eckfeldt JH, Kimmel PL, Vasan RS, Bonventre JV, Inker LA, Coresh J; Chronic Kidney Disease Biomarkers Consortium Investigators.

Am J Kidney Dis. 2018 Oct;72(4):538-546. doi: 10.1053/j.ajkd.2018.04.023. Epub 2018 Jul 18.

PMID:
30031564
8.

Clinical consequences of chemotherapy dose reduction in obese patients with stage III colon cancer: A retrospective analysis from the PETACC 3 study.

Stocker G, Hacker UT, Fiteni F, John Mahachie J, Roth AD, Van Cutsem E, Peeters M, Lordick F, Mauer M.

Eur J Cancer. 2018 Aug;99:49-57. doi: 10.1016/j.ejca.2018.05.004. Epub 2018 Jun 15.

PMID:
29906734
9.

Association of Patient Sex With Chemotherapy-Related Toxic Effects: A Retrospective Analysis of the PETACC-3 Trial Conducted by the EORTC Gastrointestinal Group.

Cristina V, Mahachie J, Mauer M, Buclin T, Van Cutsem E, Roth A, Wagner AD.

JAMA Oncol. 2018 Jul 1;4(7):1003-1006. doi: 10.1001/jamaoncol.2018.1080. No abstract available.

PMID:
29800044
10.

Role of Kidney Biopsies for Biomarker Discovery in Diabetic Kidney Disease.

Looker HC, Mauer M, Nelson RG.

Adv Chronic Kidney Dis. 2018 Mar;25(2):192-201. doi: 10.1053/j.ackd.2017.11.004. Review.

11.

Fabry disease revisited: Management and treatment recommendations for adult patients.

Ortiz A, Germain DP, Desnick RJ, Politei J, Mauer M, Burlina A, Eng C, Hopkin RJ, Laney D, Linhart A, Waldek S, Wallace E, Weidemann F, Wilcox WR.

Mol Genet Metab. 2018 Apr;123(4):416-427. doi: 10.1016/j.ymgme.2018.02.014. Epub 2018 Feb 28. Review.

12.

Urinary IgG4 and Smad1 Are Specific Biomarkers for Renal Structural and Functional Changes in Early Stages of Diabetic Nephropathy.

Doi T, Moriya T, Fujita Y, Minagawa N, Usami M, Sasaki T, Abe H, Kishi S, Murakami T, Ouchi M, Ichien G, Yamamoto K, Ikeda H, Koezuka Y, Takamatsu N, Shima K, Mauer M, Nagai K, Tominaga T.

Diabetes. 2018 May;67(5):986-993. doi: 10.2337/db17-1043. Epub 2018 Feb 28.

13.

Uric Acid and Diabetic Nephropathy Risk.

Mauer M, Doria A.

Contrib Nephrol. 2018;192:103-109. doi: 10.1159/000484284. Epub 2018 Jan 23. Review.

PMID:
29393137
14.

White blood cell fractions correlate with lesions of diabetic kidney disease and predict loss of kidney function in Type 2 diabetes.

Wheelock KM, Saulnier PJ, Tanamas SK, Vijayakumar P, Weil EJ, Looker HC, Hanson RL, Lemley KV, Yee B, Knowler WC, Hadjadj S, Najafian B, Mauer M, Nelson RG.

Nephrol Dial Transplant. 2017 Dec 1;32(12):2145. doi: 10.1093/ndt/gfx303. No abstract available.

PMID:
29088394
15.

White blood cell fractions correlate with lesions of diabetic kidney disease and predict loss of kidney function in Type 2 diabetes.

Wheelock KM, Saulnier PJ, Tanamas SK, Vijayakumar P, Weil EJ, Looker HC, Hanson RL, Lemley KV, Yee B, Knowler WC, Hadjadj S, Najafian B, Mauer M, Nelson RG.

Nephrol Dial Transplant. 2018 Jun 1;33(6):1001-1009. doi: 10.1093/ndt/gfx231.

PMID:
28992267
16.

Reduction of podocyte globotriaosylceramide content in adult male patients with Fabry disease with amenable GLA mutations following 6 months of migalastat treatment.

Mauer M, Sokolovskiy A, Barth JA, Castelli JP, Williams HN, Benjamin ER, Najafian B.

J Med Genet. 2017 Nov;54(11):781-786. doi: 10.1136/jmedgenet-2017-104826. Epub 2017 Jul 29.

17.

Challenges in conducting clinical trials in nephrology: conclusions from a Kidney Disease-Improving Global Outcomes (KDIGO) Controversies Conference.

Baigent C, Herrington WG, Coresh J, Landray MJ, Levin A, Perkovic V, Pfeffer MA, Rossing P, Walsh M, Wanner C, Wheeler DC, Winkelmayer WC, McMurray JJV; KDIGO Controversies Conference on Challenges in the Conduct of Clinical Trials in Nephrology Conference Participants.

Kidney Int. 2017 Aug;92(2):297-305. doi: 10.1016/j.kint.2017.04.019.

18.

Plasma bradykinin and early diabetic nephropathy lesions in type 1 diabetes mellitus.

Wheelock KM, Cai J, Looker HC, Merchant ML, Nelson RG, Fufaa GD, Weil EJ, Feldman HI, Vasan RS, Kimmel PL, Rovin BH, Mauer M, Klein JB; CKD Biomarkers Consortium.

PLoS One. 2017 Jul 10;12(7):e0180964. doi: 10.1371/journal.pone.0180964. eCollection 2017.

19.

VetCompanion: response and clarifications.

Mauer MP, Garcia J.

J Med Libr Assoc. 2017 Jul;105(3):293-294. doi: 10.5195/jmla.2017.187. Epub 2017 Jul 1. No abstract available.

20.

Serum cystatin C in youth with diabetes: The SEARCH for diabetes in youth study.

Kanakatti Shankar R, Dolan LM, Isom S, Saydah S, Maahs DM, Dabelea D, Reynolds K, Hirsch IB, Rodriguez BL, Mayer-Davis EJ, Marcovina S, D'Agostino R Jr, Mauer M, Mottl AK.

Diabetes Res Clin Pract. 2017 Aug;130:258-265. doi: 10.1016/j.diabres.2017.06.010. Epub 2017 Jun 12.

Supplemental Content

Loading ...
Support Center